Press Releases March 31, 2026

Picard Medical / SynCardia to Participate in Voice of the Patient Event During AZ Tech Week

Picard Medical and SynCardia to participate in patient-centric event during AZ Tech Week emphasizing advanced heart failure treatment innovation.

By Jordan Park PMI
Picard Medical / SynCardia to Participate in Voice of the Patient Event During AZ Tech Week
PMI

Picard Medical, Inc., parent company of SynCardia, announced its participation in the 'Voice of the Patient' event during Arizona Tech Week. The event will feature leading experts and patients discussing the impact and real-world benefits of SynCardia's total artificial heart technology in treating end-stage heart failure. It highlights patient experiences alongside innovation in medical technologies.

Key Points

  • Picard Medical/SynCardia will join the 'Voice of the Patient' event to elevate patient perspectives in healthcare innovation.
  • SynCardia’s total artificial heart is the only FDA and Health Canada approved device of its kind and widely used globally with over 2,100 implants.
  • Experienced clinicians and a patient will share insights, emphasizing quality of life and recovery in advanced heart failure treatment.

TUCSON, Ariz., April 01, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC (“SynCardia”), maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the “Voice of the Patient” event during AZ Tech Week, a program focused on elevating patient perspectives in healthcare innovation hosted by the Arizona Bioindustry Association (“AZBio”), the state’s leading organization representing biotechnology and medical device companies. The event will bring together patients, clinicians, and healthcare leaders to discuss the real-world impact of advanced medical technologies.

Dr. Francisco Arabia, an internationally recognized leader in heart transplantation and mechanical circulatory support, will represent the SynCardia Total Artificial Heart perspective. Dr. Arabia has participated in over 200 SynCardia Total Artificial Heart procedures as an implanting surgeon, proctor, or assisting surgeon at leading transplant and advanced heart failure programs, including Banner University Medical Center Phoenix, the Mayo Clinic in Arizona, Cedars Sinai Medical Center in Los Angeles, and the University of Arizona, among others. He will be joined by Amanda Vaji, Manager of the Mechanical Circulatory Support Program at Banner University Medical Center Phoenix, as well as a patient who will share firsthand experience with SynCardia therapy and recovery from advanced heart failure.

The broader program will feature patients, clinicians, and healthcare leaders discussing the impact of innovative therapies across a range of diseases.

The event will take place on Thursday, April 9, 2026, from 1:00 PM to 4:00 PM at the University of Arizona Health Sciences Innovation Forum in Tucson, Arizona. Registration is available at: https://www.azbio.org/events/voice-of-the-patient-az-tech-week/.

“Advanced heart failure treatment is not only about technology. It is about patients, families, recovery, and quality of life,” said Patrick NJ Schnegelsberg, CEO of the Company and of SynCardia. “We are pleased to participate in this event and support a broader conversation that brings patient experience directly into discussions about innovation and care.”

About Arizona Tech Week

Arizona Tech Week is a statewide innovation conference that brings together founders, investors, researchers, and industry leaders through a series of events hosted across Arizona. The life sciences programming is supported by AZBio. As part of this program, the “Voice of the Patient” event highlights patient perspectives across a range of diseases and medical technologies and brings together clinicians, innovators, and patients to discuss the real-world impact of healthcare innovation. The Company / SynCardia, as member of AZBio, are proud to support the “Voice of the Patient “event as part of AZ Tech Week.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart, an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com


Risks

  • The company’s reliance on regulatory approvals and acceptance of artificial heart technology may affect growth if challenges arise.
  • Patient outcomes and adoption rates could influence future commercial success and perception in the medical device sector.
  • Competition in the medical device and advanced heart failure markets could impact SynCardia’s market share and revenue projections.

More from Press Releases

Jena Acquisition Corporation II Announces Non-Compliance with Section 802.01B of the NYSE Listed Company Manual which Requires the Company to Maintain a Minimum of 300 Public Stockholders Apr 3, 2026 Midland States Bancorp, Inc. To Announce First Quarter 2026 Financial Results On Thursday, April 23 Apr 3, 2026 Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 3, 2026 Multi-Sensor Data Labeling and AI Data Operations: What Enterprise AV Teams Apr 3, 2026 Wix Announces Final Results of Modified Dutch Auction Tender Offer Apr 3, 2026